Aug 2, 2024, 01:25
Updated Clinical Practice Guidelines in Oncology for Imetelstat – MDS Foundation
MDS Foundation shared on X:
“On July 26th, 2024, the National Comprehensive Cancer Network updated its Clinical Practice Guidelines in Oncology for MDS. RYTELO™ (imetelstat) is now recommended as a Category 1 and 2A treatment for symptomatic anemia in patients with lower-risk MDS.”
Source : MDS Foundation/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 12, 2024, 23:10
Nov 12, 2024, 23:07
Nov 12, 2024, 22:58
Nov 12, 2024, 22:56
Nov 12, 2024, 22:50
Nov 12, 2024, 22:46
Nov 12, 2024, 22:43
Nov 12, 2024, 19:34